Table Graph
      published meta-analysis   sensitivity analysis   studies

sarilumab in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51] 0.59[0.23; 1.51]CORIMUNO-SARI-1 (non ICU), 202110%144NAnot evaluable deathsdetailed resultsCORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51] REMAP-CAP sarilumab, 2021 0.51 [0.25; 1.07] 0.54[0.30; 0.96]CORIMUNO-SARI-1 (non ICU), 2021, REMAP-CAP sarilumab, 202120%586seriousnot evaluable clinical deteriorationdetailed resultsCORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12] 1.01[0.48; 2.12]CORIMUNO-SARI-1 (non ICU), 202110%144NAnot evaluable clinical improvementdetailed resultsREMAP-CAP sarilumab, 2021 1.76 [1.12; 2.78] 1.76[1.12; 2.78]REMAP-CAP sarilumab, 202110%450NAnot evaluable clinical improvement (14-day)detailed resultsREMAP-CAP sarilumab, 2021 1.86 [1.20; 2.87] 1.86[1.20; 2.87]REMAP-CAP sarilumab, 202110%450NAnot evaluable death or ventilationdetailed resultsCORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22] 1.12[0.56; 2.22]CORIMUNO-SARI-1 (non ICU), 202110%144NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-02 07:26 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 553,628,646,645 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons